Non-viral gene delivery for p53.
Abnormality in the tumor suppressor gene p53 is one of the most common occurrences associated with human neoplasia. Consequently, restoration of wild-type p53 function is seen as a particularly promising approach for cancer gene therapy. In recent years, considerable research effort has centered upon developing and improving non-viral delivery systems as alternatives to viral vectors for gene delivery. These methods include the use of lipoplexes and polyplexes, and even delivery of naked DNA. Optimally effective cancer gene therapy requires treatment of metastatic as well as local disease, and to achieve this end, systemic delivery systems for therapeutic genes will be required. This review will discuss some of the recent advances in ways to improve targeting, transfection efficiency and stability for systemic, non-viral p53 gene therapy.
Pirollo
K F
KF
Departments of Oncology and Otolaryngology, Lombardi Cancer Center, Georgetown University Medical Center, TRB/E420, 3970 Reservoir Road NW, Washington, DC 20007, USA.
Xu
L
L
Chang
E H
EH
D000818:Animals; D019470:Biolistics; D004247:DNA / Q000008:administration & dosage / Q000235:genetics; D016503:Drug Delivery Systems; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D011108:Polymers / Q000008:administration & dosage
D008081:Liposomes; D011108:Polymers; D004247:DNA